NURO Quote, Financials, Valuation and Earnings

electroCore has a net margin of -256.8% compared to NeuroMetrix's net margin of -45.81%. NeuroMetrix's return on equity of -41.7% beat electroCore's return on equity of -147.07%.

NeuroMetrix has a consensus price target of --, signalling upside risk potential of 9011.62%. On the other hand electroCore has an analysts' consensus of $25.20 which suggests that it could grow by 200.72%. Given that NeuroMetrix has higher upside potential than electroCore, analysts believe NeuroMetrix is more attractive than electroCore.

NeuroMetrix has a beta of 2.153, which suggesting that the stock is 115.333% more volatile than S&P 500. In comparison electroCore has a beta of 0.244, suggesting its less volatile than the S&P 500 by 75.612%.

NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. electroCore offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. electroCore pays out -- of its earnings as a dividend.

NeuroMetrix quarterly revenues are $587.3K, which are smaller than electroCore quarterly revenues of $7M. NeuroMetrix's net income of -$1.5M is higher than electroCore's net income of -$3.2M. Notably, NeuroMetrix's price-to-earnings ratio is -- while electroCore's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 2.04x versus 2.49x for electroCore. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -256.8% compared to NeuroMetrix's net margin of -1226.82%. NeuroMetrix's return on equity of -41.7% beat VolitionRX's return on equity of --.

NeuroMetrix has a consensus price target of --, signalling upside risk potential of 9011.62%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 518.96%. Given that NeuroMetrix has higher upside potential than VolitionRX, analysts believe NeuroMetrix is more attractive than VolitionRX.

NeuroMetrix has a beta of 2.153, which suggesting that the stock is 115.333% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

NeuroMetrix quarterly revenues are $587.3K, which are larger than VolitionRX quarterly revenues of $474.5K. NeuroMetrix's net income of -$1.5M is higher than VolitionRX's net income of -$5.8M. Notably, NeuroMetrix's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 2.04x versus 35.18x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -256.8% compared to NeuroMetrix's net margin of -4291.67%. NeuroMetrix's return on equity of -41.7% beat Catheter Precision's return on equity of -65.84%.

NeuroMetrix has a consensus price target of --, signalling upside risk potential of 9011.62%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 387.69%. Given that NeuroMetrix has higher upside potential than Catheter Precision, analysts believe NeuroMetrix is more attractive than Catheter Precision.

NeuroMetrix has a beta of 2.153, which suggesting that the stock is 115.333% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

NeuroMetrix quarterly revenues are $587.3K, which are larger than Catheter Precision quarterly revenues of $96K. NeuroMetrix's net income of -$1.5M is higher than Catheter Precision's net income of -$4.1M. Notably, NeuroMetrix's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 2.04x versus 1.09x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -256.8% compared to NeuroMetrix's net margin of -10.04%. NeuroMetrix's return on equity of -41.7% beat Xtant Medical Holdings's return on equity of -35.34%.

NeuroMetrix has a consensus price target of --, signalling upside risk potential of 9011.62%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that NeuroMetrix has higher upside potential than Xtant Medical Holdings, analysts believe NeuroMetrix is more attractive than Xtant Medical Holdings.

NeuroMetrix has a beta of 2.153, which suggesting that the stock is 115.333% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

NeuroMetrix quarterly revenues are $587.3K, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. NeuroMetrix's net income of -$1.5M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, NeuroMetrix's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 2.04x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.